← Back to Clinical Trials
Recruiting NCT06962033

NCT06962033 PRIDE III Prison Interventions and HIV Prevention Collaboration

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06962033
Status Recruiting
Phase
Sponsor Yale University
Condition Hiv
Study Type INTERVENTIONAL
Enrollment 300 participants
Start Date 2024-11-05
Primary Completion 2028-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
All Conditions
Interventions
Opioid Agonist Therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 300 participants in total. It began in 2024-11-05 with a primary completion date of 2028-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The primary objective of this research project is to identify barriers to scale-up of Opioid Agonist Therapy (OAT) in the justice systems (prisons and probation) in Tajikistan, Kyrgyzstan, Moldova, and Georgia, and establish a NIATx learning collaborative to scale-up OAT, and analyze scale-up utilizing latent class growth analyses in people who inject drugs (PWID).

Eligibility Criteria

Inclusion Criteria: Aim 1: 1. Quantitative surveys for prison OAT providers * Being 18 years or older * Being currently assigned and working as a probation OAT provider for a probation site 2. ECHO procedures Aim 2: 1. Quantitative surveys for people in probation * Being 18 years or older * Screen yes to opioid injection on the online screener questionnaire * Currently in probation 2. Quantitative surveys for probation and prison officers * Being 18 years or older * Being currently assigned and working as a probation or prison officer at a probation site 3. Focus Groups (People in probation) * Being 18 years or older * Screen yes to opioid injection criteria on the online screener * Currently in probation 4. Focus Groups (Probation and prison officers) * Being 18 years or older * Being currently assigned and working as a probation or prison officer at a probation * Has more than 3 months of field experience * Works at a probation site within 25 kilometers of an OAT site Exclusion Criteria: \-

Contact & Investigator

Central Contact

David Oliveros, MPH

✉ david.oliveros@yale.edu

📞 202-805-8118

Principal Investigator

Frederick L Altice, MD

PRINCIPAL INVESTIGATOR

Yale University

Frequently Asked Questions

Who can join the NCT06962033 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Hiv. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06962033 currently recruiting?

Yes, NCT06962033 is actively recruiting participants. Contact the research team at david.oliveros@yale.edu for enrollment information.

Where is the NCT06962033 trial being conducted?

This trial is being conducted at New Haven, United States, Tbilisi, Georgia, Bishkek, Kyrgyzstan, Chisinau, Moldova and 1 additional location.

Who is sponsoring the NCT06962033 clinical trial?

NCT06962033 is sponsored by Yale University. The principal investigator is Frederick L Altice, MD at Yale University. The trial plans to enroll 300 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology